A clinical trial to assess the effectiveness of a new add-on therapy (PF-06687234) to infliximab.
About this study
The purpose of this research study was to compare the effects of the study drug, PF-06687234, with a placebo while also being treated with infliximab to find out which is better for treating ulcerative colitis (UC).
The study drug, PF-06687234 has two proteins that are connected to each other. One protein seeks out and attaches to areas of inflammation (for example the colon in UC). The second protein works to “calm down” the immune system in inflamed areas such as the colon, in UC.
PF-06687234 is an experimental drug which means that it is not an approved treatment for UC in Australia.
This study is closed to recruitment.
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.
The Clinical Trials Centre (CTC) is a dedicated, purpose-built space where we conduct clinical trials.
The CTC is located on Level 2 South. When you arrive, if you are unsure where to go, talk to one of our friendly volunteers or the information desk staff.